PMID- 24395351
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20211021
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Linking)
VI  - 117
IP  - 1
DP  - 2014 Mar
TI  - NDRG1 prognosticates the natural course of disease in WHO grade II glioma.
PG  - 25-32
LID - 10.1007/s11060-013-1357-2 [doi]
AB  - There is a lack of relevant prognostic and predictive factors in neurooncology 
      besides mutation of isocitrate dehydrogenase 1, codeletion of 1p/19q and promoter 
      hypermethylation of O (6) -methylguanine-DNA-methyltransferase. More importantly, 
      there is limited translation of these factors into clinical practice. The cancer 
      genome atlas data and also clinical correlative analyses suggest a pivotal role 
      for the epidermal growth factor receptor /protein kinase B/mammalian target of 
      rapamycin (mTOR) pathway in both biology and the clinical course of gliomas. 
      However, attempts to stratify gliomas by activating alterations in this pathway 
      have failed thus far. The tumors of 40 patients with WHO grade II gliomas without 
      immediate postoperative genotoxic treatment and known progression and survival 
      status at a median follow-up of 12.2 years were analyzed for expression of the 
      mTOR complex 2 downstream target N-myc downstream regulated gene (NDRG)1 using 
      immunohistochemistry. Baseline characteristics for NDRG1 absent/low versus 
      moderate/high patients were similar. Time to reintervention was significantly 
      longer in the NDRG1 group (P = 0.026). NDRG1 may become a novel biomarker to 
      guide the decision which WHO degrees II glioma patients may be followed without 
      postsurgical intervention and which patients should receive genotoxic treatment 
      early on. Validation of this hypothesis will be possible with the observational 
      arm of the RTOG 9802 and the pretreatment step of the EORTC 22033/26032 trials.
FAU - Blaes, J
AU  - Blaes J
AD  - German Cancer Consortium (DKTK), Clinical Cooperation Units Neurooncology, German 
      Cancer Research Center (DKFZ), Heidelberg, Germany.
FAU - Weiler, M
AU  - Weiler M
FAU - Sahm, F
AU  - Sahm F
FAU - Hentschel, B
AU  - Hentschel B
FAU - Osswald, M
AU  - Osswald M
FAU - Czabanka, M
AU  - Czabanka M
FAU - Thome, C M
AU  - Thome CM
FAU - Schliesser, M G
AU  - Schliesser MG
FAU - Pusch, S
AU  - Pusch S
FAU - Luger, S
AU  - Luger S
FAU - Winkler, F
AU  - Winkler F
FAU - Radbruch, A
AU  - Radbruch A
FAU - Jugold, M
AU  - Jugold M
FAU - Simon, M
AU  - Simon M
FAU - Steinbach, J P
AU  - Steinbach JP
FAU - Schackert, G
AU  - Schackert G
FAU - Tatagiba, M
AU  - Tatagiba M
FAU - Westphal, M
AU  - Westphal M
FAU - Tonn, J C
AU  - Tonn JC
FAU - Gramatzki, D
AU  - Gramatzki D
FAU - Pietsch, T
AU  - Pietsch T
FAU - Hartmann, C
AU  - Hartmann C
FAU - Glimm, H
AU  - Glimm H
FAU - Vajkoczy, P
AU  - Vajkoczy P
FAU - von Deimling, A
AU  - von Deimling A
FAU - Platten, M
AU  - Platten M
FAU - Weller, M
AU  - Weller M
FAU - Wick, W
AU  - Wick W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140107
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (N-myc downstream-regulated gene 1 protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Astrocytoma/diagnosis/metabolism/pathology/therapy
MH  - Biomarkers, Tumor/metabolism
MH  - Brain Neoplasms/*diagnosis/*metabolism/pathology/therapy
MH  - Cell Cycle Proteins/*metabolism
MH  - Follow-Up Studies
MH  - Glioma/*diagnosis/*metabolism/pathology/therapy
MH  - Humans
MH  - Immunohistochemistry
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Oligodendroglioma/diagnosis/metabolism/pathology/therapy
MH  - Prognosis
MH  - Prospective Studies
MH  - Retreatment
MH  - Survival Analysis
MH  - Time Factors
EDAT- 2014/01/08 06:00
MHDA- 2014/11/02 06:00
CRDT- 2014/01/08 06:00
PHST- 2013/10/16 00:00 [received]
PHST- 2013/12/31 00:00 [accepted]
PHST- 2014/01/08 06:00 [entrez]
PHST- 2014/01/08 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - 10.1007/s11060-013-1357-2 [doi]
PST - ppublish
SO  - J Neurooncol. 2014 Mar;117(1):25-32. doi: 10.1007/s11060-013-1357-2. Epub 2014 
      Jan 7.